The idea of co-targeting ERα and PARP1 is supported by reports that showed that a combination of tamoxifen and talazoparib sensitized breast cancer cells to tamoxifen through the reduction of ERα poly-ADP-ribosylation [27]. The gene discussed is PARP1; the disease is breast cancer.